Prostate Health on TRT – 12 Rules to Live by on Testosterone – Doctor’s Guide

Prostate health on testosterone therapy is framed as a long-term priority for aging men. The transcript argues that prostate problems often become more important than cosmetic goals over time. Prostate cancer is addressed first, because many men fear testosterone will create malignancy. The discussion states that TRT does not cause prostate cancer in men who start cancer free. Controversy is described around giving testosterone to men with known cancer history or risk. Because evidence evolves, specialist urology input is emphasized for individualized decision making. The segment sets a prevention mindset, treating screening as routine rather than alarming.

PSA testing is reviewed as a screening marker that must be interpreted using trends and context. Baseline PSA before TRT is emphasized so later changes can be compared accurately over time. A rising PSA triggers discussion of next steps, including repeat testing and careful evaluation. The transcript warns against rushing straight into random biopsy without better risk assessment. Prostate MRI is described as a more modern approach that can guide targeted biopsy decisions. Cancer concern is balanced against benign causes, because infection and inflammation can mimic danger. Men are encouraged to view prostate decisions as structured medicine rather than internet panic.

Benign prostatic hyperplasia is described as a common cause of urinary obstruction and nocturia. Prostatitis is discussed as infectious or noninfectious inflammation that can raise PSA readings. Lower urinary tract symptoms are emphasized, including weak stream and incomplete bladder emptying. Testosterone can worsen BPH clinically, especially when doses are higher or stacking occurs. Alpha blockers such as tamsulosin and alfuzosin are mentioned, with dizziness risk explained clearly. Tadalafil is highlighted as an FDA-cleared BPH option that also supports erectile function pathways. When symptoms persist, procedures like TURP are discussed, and careful urologist involvement is urged.